Dravet syndrome is an epileptic condition with a 15 to 20 percent mortality rate and resistant to current medications. Tel Aviv University researchers have discovered that the DHODH gene is key to triggering such adverse neural activity and that Terflunomide can inhibit it.

https://www.jns.org/israeli-scientists-discover-potential-new-epilepsy-treatment/